Gene therapy is poised to make a commercial breakthrough after Oxford BioMedica agreed global rights for a cancer treatment with Sanofi-Aventis, in a deal with a headline value of €518 million.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and the fortnightly R&D Express, tracking reforms and investments in central and eastern Europe.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.